Loading…
Employees: 986
Size Oxford BioMedica (OXB.L) is a United Kingdom Health Care company (Biotechnology) with a market value of $892M, the 227th largest of 363 United Kingdom companies the cockpit tracks. Shares closed at £546.00 on 6 Nov 2026.
Performance Over six months the shares fell 14.0%, against -12.2% for the median peer and +3.6% for the United Kingdom market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 16.0% over the last twelve months (peer median +0.2%); the operating margin is -18.2% (peer median -27.1%).
Valuation It trades at 4.3× enterprise value to sales against a peer median of 8.8× (5th cheapest of 19).
Capital Return on invested capital runs 33.5 points below its cost of capital (16.5% WACC).
Next results Next results expected around 15 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | £175M | £169M | £129M | £89.5M | £140M |
| Revenue growth | — | +31% | +44% | -36% | — |
| Gross profit | £62.7M | £65.3M | £52.4M | £39.2M | £69.1M |
| EBITDA | -£13.3M | -£9.12M | -£23.3M | -£60.1M | -£28.3M |
| Net income | -£40.7M | -£30.1M | -£43.2M | -£157M | -£39.2M |
| Free cash flow | -£32.5M | -£6.46M | -£58.1M | -£38.2M | -£33.0M |
| Capital expenditure | £10.4M | £4.76M | £7.50M | £9.83M | £16.3M |
| Total debt | n/a | £148M | £109M | £111M | £114M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OXB.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.4% | -5.4% | 4th highest of 21 |
| 6-month return | -14.0% | -12.2% | 10th lowest of 20 |
| Distance from 52-week high | -43.2% | -40.0% | 8th lowest of 21 |
| Revenue growth (TTM) | +16.0% | +0.2% | 5th highest of 18 |
| Operating margin | -18.2% | -27.1% | 8th highest of 19 |
| EV / Sales | 4.3× | 8.8× | 5th cheapest of 19 |
| ROIC minus cost of capital | -33.5 pp | -7.5 pp | 3rd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | 4.3× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | 11.1× | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | 14,560.9× | n/a | n/a |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 5.7× | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | 2.1× | -9.9% | +39.2% |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | 208.9× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | 3.5× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | 26.5× | n/a | n/a |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 6.6× | n/a | n/a |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | 211.3× | n/a | n/a |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 1.4× | 6.6% | +4.4% |
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 4.7× | 8.8% | +2.4% |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $803M | -12% | +21% | 11% | 3.9× | 20.1% | +11.8% |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $803M | +91% | -15% | -8% | 17.9× | 48.8% | +14.7% |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 4.7× | 11.1% | +2.3% |
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | 7.6× | -12.3% | -10.9% |
| Changchun BCHT Biotechnology 688276.SS | China | $1.00B | -11% | +2% | -29% | 10.0× | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $1.02B | -4% | -28% | 11% | 16.3× | 42.9% | -16.6% |
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | 11.1× | n/a | n/a |